MSD is working with Seattle Genetics on two new oncology projects
Last Update: 2021-03-05
Search more information of high quality chemicals, good prices and reliable suppliers, visit
, known as Merck in the U.S. and Canada, announced two new oncology collaborations with biotech company and oncologist Seattle Genetics.
As part of the agreement, the two companies will jointly develop and commercialize Seattle's commercialized research antibody, the drug ladiratuzumab vedotin, which is currently in Phase II clinical trials of breast cancer and other solid tumors.
The collaboration evaluates ADC as a monotherapy and works with MSD's PD-1 inhibitor Keytruda (Pim monoanti) to treat triple-negative breast cancer, hormone-positive breast cancer, and other solid tumors expressing LIV-1.
Under the terms of the deal, Seattle will receive an advance of $600 million, while MSD will invest $1 billion in the company's 5 million shares at $200 a share. Most importantly, Seattle is also eligible for a milestone payment of up to $2.6 billion in progress related to the Radirato Single Antivedotin Clinical Program.
In another agreement, Seattle also granted MSD exclusive license to sell Tucatinib, a small molecule tyrosine kinase inhibitor used to treat HER-2-positive cancers, in Asia, the Middle East and Latin America, and elsewhere. Outside the United States, Canada, and Europe.
MSD will pay Seattle $125 million for the exclusive license, and Seattle will be eligible for a progress-related milestone of up to $65 million.
“ Our partnership with Mercadon on Ladiratuzumab vedotin will enable us to accelerate and expand its development program for breast cancer and other solid tumors, including with Merck's Keytruda, while also enabling us to leverage our commercial operations in the United States and Europe," said Clay Siegall, President and CEO of Seattle Genetics.
He added: "A strategic partnership with Tukysa will help us attract more patients globally and benefit from the strong commercial strength of one of the world's leading pharmaceutical companies." Roger M. Perlmutter, president of
Merck Research Laboratories, said, "These two strategic partnerships will enable us to further diversify Merck's broad portfolio and product line of oncology treatments and continue to expand and improve the lives of as many cancer patients as possible." ”（cyy123.com）
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.